FLECAINIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C17H20F6N2O3
Molecular Weight	414.3427
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(=C1)C(=O)NCC2CCCCN2

InChI

InChIKey=DJBNUMBKLMJRSA-UHFFFAOYSA-N

InChI=1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB01195
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/flecainide.html

Flecainide is a potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial arrhythmias and tachycardias. Flecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the IC class of antiarrhythmics. Flecainide acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers. Flecainide is a sodium channel blocker, binding to voltage gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. Flecainide is sold under the trade name Tambocor (manufactured by 3M pharmaceuticals). Flecainide went off-patent on February 10, 2004. In addition to being marketed as Tambocor, it is also available in generic version and under the trade names Almarytm, Apocard, Ecrinal, and Flécaine.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Sodium channel protein type V alpha subunit 49 Target ID: CHEMBL1980 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21194571	Inhibitor 8504	67.2 µM [IC50]
Sodium channel protein type IV alpha subunit 23 Target ID: CHEMBL2072 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20590641	Inhibitor 8504	18.0 µM [Ki]
HERG 99 Target ID: CHEMBL240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26159617	Inhibitor 8504	1.49 µM [IC50]
Voltage-gated potassium channel subunit Kv4.3 7 Target ID: CHEMBL1964 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12875427	Inhibitor 8504	7.8 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Paroxysmal atrial fibrillation 2 Sources: https://www.drugs.com/pro/flecainide.html	Preventing		Approved 8583	Flecainide Approved Use In patients without structural heart disease, Flecainide is indicated for the prevention of - paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide is also indicated for the prevention of - documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician, are lifethreatening. Launch Date 2001
Documented ventricular arrhythmias 2 Sources: https://www.drugs.com/pro/flecainide.html	Preventing		Approved 8583	Flecainide Approved Use In patients without structural heart disease, Flecainide is indicated for the prevention of - paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide is also indicated for the prevention of - documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician, are lifethreatening. Launch Date 2001

C_max

Value	Dose	Co-administered	Analyte	Population
1710 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3094570	2 mg/kg single, intravenous dose: 2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		FLECAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
355 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3094570	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		FLECAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
5.9 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1782978	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	FLECAINIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6238 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3094570	2 mg/kg single, intravenous dose: 2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	FLECAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5979 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3094570	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	FLECAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
11.5 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1782978	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		FLECAINIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
60% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/6364769			FLECAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20562156	healthy, 18 Health Status: healthy Age Group: 18 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/20562156	Disc. AE: Unconsciousness, Cyanosis... AEs leading to discontinuation/dose reduction: Unconsciousness Cyanosis Bradycardia Arrhythmia Sources: https://pubmed.ncbi.nlm.nih.gov/20562156
3800 mg single, oral Overdose Dose: 3800 mg Route: oral Route: single Dose: 3800 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3107447	healthy, 28 Health Status: healthy Age Group: 28 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/3107447	Disc. AE: Polymorphic ventricular tachycardia... AEs leading to discontinuation/dose reduction: Polymorphic ventricular tachycardia Sources: https://pubmed.ncbi.nlm.nih.gov/3107447
10 g single, oral Overdose Dose: 10 g Route: oral Route: single Dose: 10 g Sources: https://pubmed.ncbi.nlm.nih.gov/9825278	healthy, 36 Health Status: healthy Age Group: 36 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/9825278	Disc. AE: Ventricular tachycardia, Hypotension... AEs leading to discontinuation/dose reduction: Ventricular tachycardia Hypotension Cardiopulmonary arrest Sources: https://pubmed.ncbi.nlm.nih.gov/9825278
1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Sources: https://pubmed.ncbi.nlm.nih.gov/27884575	unhealthy, 62 Health Status: unhealthy Age Group: 62 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/27884575	Disc. AE: Brugada syndrome, Mental status changes... AEs leading to discontinuation/dose reduction: Brugada syndrome Mental status changes Fatigue Sources: https://pubmed.ncbi.nlm.nih.gov/27884575
200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display	Disc. AE: Ventricular tachycardia, Cardiac arrest... AEs leading to discontinuation/dose reduction: Ventricular tachycardia Cardiac arrest Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display

AEs

AE	Significance	Dose	Population
Arrhythmia	Disc. AE	1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20562156	healthy, 18 Health Status: healthy Age Group: 18 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/20562156
Bradycardia	Disc. AE	1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20562156	healthy, 18 Health Status: healthy Age Group: 18 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/20562156
Cyanosis	Disc. AE	1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20562156	healthy, 18 Health Status: healthy Age Group: 18 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/20562156
Unconsciousness	Disc. AE	1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20562156	healthy, 18 Health Status: healthy Age Group: 18 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/20562156
Polymorphic ventricular tachycardia	Disc. AE	3800 mg single, oral Overdose Dose: 3800 mg Route: oral Route: single Dose: 3800 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3107447	healthy, 28 Health Status: healthy Age Group: 28 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/3107447
Cardiopulmonary arrest	Disc. AE	10 g single, oral Overdose Dose: 10 g Route: oral Route: single Dose: 10 g Sources: https://pubmed.ncbi.nlm.nih.gov/9825278	healthy, 36 Health Status: healthy Age Group: 36 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/9825278
Hypotension	Disc. AE	10 g single, oral Overdose Dose: 10 g Route: oral Route: single Dose: 10 g Sources: https://pubmed.ncbi.nlm.nih.gov/9825278	healthy, 36 Health Status: healthy Age Group: 36 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/9825278
Ventricular tachycardia	Disc. AE	10 g single, oral Overdose Dose: 10 g Route: oral Route: single Dose: 10 g Sources: https://pubmed.ncbi.nlm.nih.gov/9825278	healthy, 36 Health Status: healthy Age Group: 36 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/9825278
Brugada syndrome	Disc. AE	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Sources: https://pubmed.ncbi.nlm.nih.gov/27884575	unhealthy, 62 Health Status: unhealthy Age Group: 62 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/27884575
Fatigue	Disc. AE	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Sources: https://pubmed.ncbi.nlm.nih.gov/27884575	unhealthy, 62 Health Status: unhealthy Age Group: 62 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/27884575
Mental status changes	Disc. AE	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Sources: https://pubmed.ncbi.nlm.nih.gov/27884575	unhealthy, 62 Health Status: unhealthy Age Group: 62 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/27884575
Cardiac arrest	Disc. AE	200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display
Ventricular tachycardia	Disc. AE	200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	inhibitor 2438	substrate 1388 inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT2 779	CYP1A2 1197

Drug as perpetrator

Target	Modality	Activity
CYP2D6 2546	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/8801060/	yes [IC50 0.44 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/8801060/	yes [IC50 0.49 uM]
OCT2 782	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/19002438/	yes [IC50 191 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP1A2 1197	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732943/	yes
CYP2D6 1388	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732943/	yes		yes (co-administration study) Comment: During the period in which the CYP2D6 inhibitor paroxetine was administered, the flecainide AUC in extensive and intermediate metabolizers was increased to 128.5% of basal values (90% CI, 122.2%– 135.2%) and 116.6% of basal values (90% CI, 107.3%–126.8%). However, poor metabolizers exhibited no alterations in AUC after administration of paroxetine (pharmacogenomic studies were also performed) Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732943/

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1573407/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:75984	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:75984
ChemicalBook	CB0663265	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0663265
eMolecules	901891	https://www.emolecules.com/cgi-bin/more?vid=901891
MolPort	MolPort-003-847-380	https://www.molport.com/shop/molecule-link/MolPort-003-847-380

PubMed

Title	Date	PubMed
Flecainide acetate in the treatment of tachycardias associated with Mahaim fibres.	1987 Aug	3117552
[Drug-induced intrahepatic cholestasis caused by flecainide acetate and enalapril].	1987 Mar	3034817
Rapid suppression of flecainide-induced incessant ventricular tachycardia with high-dose intravenous amiodarone.	1988 Apr	3127126
[Central nervous system side effects due to anti-arrhythmia therapy. Psychotic depression due to flecainide].	1988 Mar 11	3127189
Torsades de pointe with flecainide-amiodarone therapy.	1990	2120306
Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators.	1991 Dec 15	1720917
Safety and efficacy of oral flecainide therapy in patients with atrioventricular re-entrant tachycardia.	1991 Feb 1	1898629
Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide.	1991 Jan 15	1898998
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.	1991 Mar 21	1900101
Flecainide in quinidine-resistant atrial fibrillation.	1992 Aug 20	1510001
Long-term safety and efficacy of flecainide in the treatment of supraventricular tachyarrhythmias: the United States experience. The Flecainide Supraventricular Tachyarrhythmia Investigators.	1992 Aug 20	1509993
Asystole and cardiogenic shock due to combined treatment with verapamil and flecainide.	1992 Aug 29	1354292
Pseudo infarction ECG pattern occurring during intravenous treatment with flecainide acetate.	1992 Jan	1577021
Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST Investigators.	1992 Jul	1607582
Efficacy of flecainide, sotalol, and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality.	1992 Oct	1449923
Flecainide induced peripheral neuropathy.	1992 Oct 3	1330141
A randomized double-blind crossover study comparing the efficacy and tolerability of flecainide and quinidine in the control of patients with symptomatic paroxysmal atrial fibrillation.	1992 Sep	1514492
Successful extracorporeal life support in a case of severe flecainide intoxication.	2001 Apr	11373489
[Protocols for the treatment of supraventricular tachycardias in the fetus].	2001 Jun 23	11447879
Supraventricular tachycardia with hydrops in a 27-week premature baby.	2001 Oct	11695082
Symptomatic bradycardia secondary to interaction between topical timolol maleate, verapamil, and flecainide: a case report.	2002 Apr	11932086
Characterisation of the human voltage-gated potassium channel gene, KCNA7, a candidate gene for inherited cardiac disorders, and its exclusion as cause of progressive familial heart block I (PFHBI).	2002 Jan	11896454
Selection of drugs to test the specificity of the Tg.AC assay by screening for induction of the gadd153 promoter in vitro.	2003 Aug	12730611
Flecainide test in Brugada syndrome: a reproducible but risky tool.	2003 Jan	12687841
Safety and feasibility of a clinical pathway for the outpatient initiation of antiarrhythmic medications in patients with atrial fibrillation or atrial flutter.	2003 Jun 15	12804730
Flecainide induced ventricular fibrillation in a neonate.	2003 Oct	12975443
Flecainide induced ventricular tachycardia (torsades de pointes).	2003 Sep	12930510
Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents.	2004 Aug 18	15312873
Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels.	2004 Jul	15272206
Brugada pattern electrocardiographic changes associated with profound electrolyte disturbance.	2004 Jul	15271030
Different clinical courses and predictors of atrial fibrillation occurrence after transisthmic ablation in patients with preablation lone atrial flutter, coexistent atrial fibrillation, and drug induced atrial flutter.	2004 Nov	15546305
Electrocardiographical case. Asymptomatic patient with ST-segment elevation.	2004 Nov	15510328
Flecainide overdose--support using an intra-aortic balloon pump.	2005 Dec 12	16343338
A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system.	2005 Feb	15342952
Long-term results of hybrid therapy in patients with atrial fibrillation who develop atrial flutter during flecainide infusion.	2005 Jan	15683478
Assessment of serum flecainide trough levels in patients with tachyarrhythmia.	2005 Jan	15638992
[Prevalence of Brugada syndrome among 35,309 inhabitants of Lorraine screened at a preventive medicine centre].	2005 Mar	15816318
Flecainide-induced neuropathy.	2005 Sep	16076915
Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE.	2006 Dec	16931536
[Intravenous flecainide administration for conversion of paroxysmal atrial fibrillation in the emergency room].	2006 May	16805213
[Life-threatening ventricular tachycardia during flecainide treatment for symptomatic atrial fibrillation in a patient with a structural cardiac disorder].	2006 May 6	16715868
Torsade-de-pointes in a patient under flecainide treatment, an unusual case of proarrhythmicity.	2007 Jan 8	17056139
Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells.	2007 Mar	17175557
Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes.	2007 May	17467628
Flecainide cardiotoxicity precipitated by electrolyte imbalance. Caution with thiazide diuretics.	2007 May	17452686
Role of cytochrome P450 in drug interactions.	2008 Oct 18	18928560
A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology.	2009 Apr	19174378
Effects of antiarrhythmic drugs on the hyperpolarization-activated cyclic nucleotide-gated channel current.	2009 Jun	19498275
A case of flecainide-induced hyponatremia.	2009 Oct	19298558
Iatrogenic Flecainide toxicity.	2010 Dec	20736205

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Ventricular Tachycardia Initial dose: 100 mg orally every 12 hours. Maintenance dose: May be increased in increments of 50 mg bid every 4 days until efficacy is achieved. Most patients with SUSTAINED VT do not require more than 150 mg every 12 hours (300 mg/day), and the maximum dose recommended is 400 mg/day. Usual Adult Dose for Atrial Fibrillation Initial dose: 50 mg orally every 12 hours. Maintenance dose: May be increased in increments of 50 mg bid every 4 days until efficacy is achieved.

Route of Administration: Oral

In Vitro Use Guide

Flecainide produced a dose-dependent prolongation of the cardiac action potential at 1 and 3uM in human pluripotent stem cell-derived cardiomyocytes.

Name

Type

Language

NSC-719273

Preferred Name

English

FLECAINIDE

Official Name

English

N-(2-PIPERIDYLMETHYL)-2,5-BIS(2,2,2-TRIFLUOROETHOXY)BENZAMIDE

Systematic Name

English

FLECAINIDE [VANDF]

Common Name

English

THN102 COMPONENT FLECAINIDE

Common Name

English

THN-102 COMPONENT FLECAINIDE

Code

English

Flecainide [WHO-DD]

Common Name

English

FLECAINIDE [MI]

Common Name

English

flecainide [INN]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175426